| scholarly article | Q13442814 |
| P2093 | author name string | Xuemin Sun | |
| Leslie Michels Thompson | |||
| Frank M LaFerla | |||
| Kim N Green | |||
| Joan S Steffan | |||
| Hilda Martinez-Coria | |||
| Steven S Schreiber | |||
| P2860 | cites work | The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase | Q24296836 |
| Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules | Q24302556 | ||
| Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition | Q27633064 | ||
| Resveratrol improves health and survival of mice on a high-calorie diet | Q27860950 | ||
| Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae | Q27931494 | ||
| Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans | Q28131824 | ||
| Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan | Q28203572 | ||
| Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules | Q28282209 | ||
| Degradation of microtubule-associated protein 2 and brain spectrin by calpain: a comparative study | Q48727017 | ||
| Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease | Q48934697 | ||
| Hippocampus, amygdala, and memory deficits in rats | Q49100759 | ||
| Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. | Q50951137 | ||
| Sorting of Fas ligand to secretory lysosomes is regulated by mono-ubiquitylation and phosphorylation. | Q53582778 | ||
| Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants | Q73131783 | ||
| Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease | Q28307422 | ||
| A specific amyloid-beta protein assembly in the brain impairs memory | Q28854597 | ||
| Sirtuin activators mimic caloric restriction and delay ageing in metazoans | Q29547766 | ||
| Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction | Q29547778 | ||
| Histone acetyltransferases | Q29547823 | ||
| Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila | Q29616737 | ||
| Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 | ||
| Recovery of learning and memory is associated with chromatin remodelling | Q29619784 | ||
| Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice | Q29619786 | ||
| Safety of high-dose nicotinamide: a review | Q33928940 | ||
| Histone deacetylase inhibitors reduce polyglutamine toxicity | Q33953013 | ||
| No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia | Q34084199 | ||
| Histone acetylation and disease | Q34298969 | ||
| A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule | Q34345777 | ||
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease | Q34763178 | ||
| An Alzheimer's disease hypothesis based on transcriptional dysregulation | Q35215414 | ||
| Histone deacetylase inhibitors open new doors in cancer therapy | Q35864048 | ||
| Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau | Q35911885 | ||
| A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data | Q36441017 | ||
| Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease | Q36740290 | ||
| Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. | Q36967971 | ||
| Abeta inhibits the proteasome and enhances amyloid and tau accumulation | Q37147213 | ||
| MAP2c, but not tau, binds and bundles F-actin via its microtubule binding domain | Q38343473 | ||
| SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock | Q40118969 | ||
| Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly | Q40878824 | ||
| Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease | Q42855049 | ||
| Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice | Q44182586 | ||
| The cytoskeleton in Alzheimer disease. | Q44432507 | ||
| Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice | Q44619618 | ||
| Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy | Q44854729 | ||
| Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. | Q44889180 | ||
| Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases | Q44978542 | ||
| Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. | Q45207540 | ||
| Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles | Q46332461 | ||
| Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. | Q46483776 | ||
| Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice | Q46526611 | ||
| Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice | Q46663967 | ||
| Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. | Q46765311 | ||
| Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. | Q46856839 | ||
| A brain-specific activator of cyclin-dependent kinase 5. | Q48079027 | ||
| Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses | Q48130989 | ||
| Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression | Q48241008 | ||
| Acetylated and detyrosinated alpha-tubulins are co-localized in stable microtubules in rat meningeal fibroblasts | Q48246728 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| niacinamide | Q192423 | ||
| selective reduction | Q3153583 | ||
| P304 | page(s) | 11500-10 | |
| P577 | publication date | 2008-11-05 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau | |
| P478 | volume | 28 |
| Q30578694 | A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease |
| Q36037588 | A reversible early oxidized redox state that precedes macromolecular ROS damage in aging nontransgenic and 3xTg-AD mouse neurons |
| Q64269308 | Age- and AD-related redox state of NADH in subcellular compartments by fluorescence lifetime imaging microscopy |
| Q47578572 | Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer's disease. |
| Q28943540 | Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study |
| Q35855587 | Alzheimer's disease and the amyloid cascade hypothesis: a critical review |
| Q33349401 | Alzheimer's disease: clinical trials and drug development |
| Q89964362 | Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review |
| Q90330853 | Application of Response Surface Method for Preparation, Optimization, and Characterization of Nicotinamide Loaded Solid Lipid Nanoparticles |
| Q37987323 | Autophagy: a double-edged sword in Alzheimer's disease |
| Q37612400 | Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells |
| Q34525891 | CDK5 activator protein p25 preferentially binds and activates GSK3β |
| Q37570600 | Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology |
| Q28384232 | Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders |
| Q47110701 | Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy |
| Q35908248 | Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice |
| Q37737296 | Current therapeutic targets for the treatment of Alzheimer's disease |
| Q33720139 | Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. |
| Q47883352 | Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death |
| Q34328541 | Dimethyl sulfoxide induces both direct and indirect tau hyperphosphorylation. |
| Q37390739 | Disease-modifying drugs in Alzheimer's disease |
| Q34516825 | Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease |
| Q90512417 | Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide |
| Q34618914 | Does Huntingtin play a role in selective macroautophagy? |
| Q43618382 | Dual-energy precursor and nuclear erythroid-related factor 2 activator treatment additively improve redox glutathione levels and neuron survival in aging and Alzheimer mouse neurons upstream of reactive oxygen species |
| Q35174844 | Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model |
| Q28533783 | Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AβPPswe-PS1dE9 mice |
| Q39401700 | Emerging Roles of Sirtuins in Ischemic Stroke. |
| Q28304384 | Environmental enrichment and brain repair: harnessing the therapeutic effects of cognitive stimulation and physical activity to enhance experience-dependent plasticity |
| Q38199061 | Environmental factors in the development and progression of late-onset Alzheimer's disease |
| Q47288935 | Epigenetic Drug Repositioning for Alzheimer's Disease Based on Epigenetic Targets in Human Interactome |
| Q38225708 | Epigenetic drug discovery for Alzheimer's disease |
| Q34294750 | Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders |
| Q36682567 | Epigenetic mechanisms in neurological disease |
| Q39090345 | Epigenetics in Alzheimer's Disease: Perspective of DNA Methylation |
| Q36956287 | Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease |
| Q46853871 | Ex vivo protective effects of nicotinamide and 3-aminobenzamide on rat synaptosomes treated with Aβ(1-42). |
| Q35960986 | Finding Potent Sirt Inhibitor in Coffee: Isolation, Confirmation and Synthesis of Javamide-II (N-Caffeoyltryptophan) as Sirt1/2 Inhibitor |
| Q83158496 | Food for thought |
| Q28748304 | Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease |
| Q53428761 | GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia. |
| Q34368728 | Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Aβ or tau pathology |
| Q38600194 | Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma |
| Q38197952 | Glial epigenetics in neuroinflammation and neurodegeneration |
| Q37685428 | HDAC inhibitors and neurodegeneration: at the edge between protection and damage |
| Q94544744 | Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation |
| Q37602632 | Histone deacetylases as targets for the treatment of human neurodegenerative diseases |
| Q42607789 | Impact of a multi-nutrient diet on cognition, brain metabolism, hemodynamics, and plasticity in apoE4 carrier and apoE knockout mice |
| Q57842300 | Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson’s Disease Patients |
| Q35748624 | Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease |
| Q30388525 | Insights into Lysine Deacetylation of Natively Folded Substrate Proteins by Sirtuins. |
| Q48585649 | Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease. |
| Q33817811 | Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle |
| Q37419731 | Longitudinal study of differential protein expression in an Alzheimer's mouse model lacking inducible nitric oxide synthase |
| Q34038935 | Low HDL Cholesterol is Associated with Lower Gray Matter Volume in Cognitively Healthy Adults. |
| Q41197258 | Lycopene Pretreatment Ameliorates Acute Ethanol Induced NAD(+) Depletion in Human Astroglial Cells. |
| Q38085375 | Lysine acetyltransferases CBP and p300 as therapeutic targets in cognitive and neurodegenerative disorders. |
| Q37190538 | Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease |
| Q39251141 | Metabolic Vulnerability in the Neurodegenerative Disease Glaucoma |
| Q26992212 | Metabolism, longevity and epigenetics |
| Q39677617 | Mitochondrial Metabolism Power SIRT2-Dependent Deficient Traffic Causing Alzheimer's-Disease Related Pathology |
| Q26824514 | Mitochondrial targets for pharmacological intervention in human disease |
| Q37407855 | Multiple roles of HDAC inhibition in neurodegenerative conditions. |
| Q90438582 | NAD+ in Brain Aging and Neurodegenerative Disorders |
| Q100490695 | NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential |
| Q35558250 | Neonatal isoflurane exposure induces neurocognitive impairment and abnormal hippocampal histone acetylation in mice |
| Q64055137 | Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide |
| Q51164013 | Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration. |
| Q91903589 | Nicotinamide Augments the Anti-Inflammatory Properties of Resveratrol through PARP1 Activation |
| Q47556627 | Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum |
| Q38190088 | Nicotinamide and neurocognitive function |
| Q89599644 | Nicotinamide attenuates the decrease in dendritic spine density in hippocampal primary neurons from 5xFAD mice, an Alzheimer's disease animal model |
| Q30537554 | Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession |
| Q34373713 | Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease |
| Q39247299 | Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells |
| Q58549618 | Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer's disease animal model by reducing Tau hyperphosphorylation |
| Q37180789 | Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons |
| Q33518638 | Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats |
| Q36784219 | Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models |
| Q46979323 | Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Aβ(1-42)-induced rat model of Alzheimer's disease. |
| Q28730781 | Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra |
| Q99238404 | Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease |
| Q47098865 | Nicotinamide: a novel treatment for age-related macular degeneration? |
| Q91246348 | Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease |
| Q36065099 | Nutrition and dementia |
| Q49652662 | Nutrition: Review on the Possible Treatment for Alzheimer's Disease |
| Q36617072 | Opening the genome to reduce cocaine-seeking behavior |
| Q93080138 | Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau |
| Q35795263 | Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins |
| Q58555658 | Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases |
| Q37947768 | Pharmacological treatment of Alzheimer disease |
| Q46162286 | Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model |
| Q55517090 | Phosphorylation of different tau sites during progression of Alzheimer's disease. |
| Q37447680 | Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity |
| Q38041123 | Potential of chromatin modifying compounds for the treatment of Alzheimer's disease |
| Q34014237 | Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials |
| Q39197675 | Probing signal amplification by reversible exchange using an NMR flow system |
| Q46495521 | Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system. |
| Q37265815 | Radiation-Induced Alteration of the Brain Proteome: Understanding the Role of the Sirtuin 2 Deacetylase in a Murine Model |
| Q33856674 | Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation |
| Q30428450 | Regulation of histone acetylation in the hippocampus of chronically stressed rats: a potential role of sirtuins |
| Q50617586 | Relative efficacy of nicotinamide treatment of a mouse model of infantile Niemann-Pick C1 disease. |
| Q40114950 | Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease |
| Q35958359 | Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases |
| Q54255866 | SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. |
| Q38747012 | SIRT1 Overexpression in Mouse Hippocampus Induces Cognitive Enhancement Through Proteostatic and Neurotrophic Mechanisms |
| Q46772238 | SIRT1 Regulates Cognitive Performance and Ability of Learning and Memory in Diabetic and Nondiabetic Models |
| Q35158382 | SIRT1 in the brain-connections with aging-associated disorders and lifespan |
| Q39574276 | ST101 induces a novel 17 kDa APP cleavage that precludes Aβ generation in vivo |
| Q44493438 | Simultaneously improving the mechanical properties, dissolution performance, and hygroscopicity of ibuprofen and flurbiprofen by cocrystallization with nicotinamide. |
| Q55636051 | Sir-2.1 mediated attenuation of α-synuclein expression by Alaskan bog blueberry polyphenols in a transgenic model of Caenorhabditis elegans. |
| Q33986353 | Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. |
| Q33914623 | Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease |
| Q39636393 | Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer's Disease Mouse Models |
| Q30411171 | Sirtuin activity in dentate gyrus contributes to chronic stress-induced behavior and extracellular signal-regulated protein kinases 1 and 2 cascade changes in the hippocampus |
| Q38108128 | Sirtuin deacetylases in neurodegenerative diseases of aging |
| Q36523200 | Sirtuins Function as the Modulators in Aging-related Diseases in Common or Respectively |
| Q58707338 | Sirtuins in Neuroendocrine Regulation and Neurological Diseases |
| Q35661567 | Sirtuins in neurodegenerative diseases: a biological-chemical perspective |
| Q35972860 | Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity |
| Q35224092 | Targeting HDACs: a promising therapy for Alzheimer's disease. |
| Q38472413 | Tau and neurodegenerative disorders |
| Q27670648 | The Bicyclic Intermediate Structure Provides Insights into the Desuccinylation Mechanism of Human Sirtuin 5 (SIRT5) |
| Q39091771 | The Current State of NAD(+) -Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets |
| Q59798711 | The Epigenetics of Alzheimer’s Disease: Factors and Therapeutic Implications |
| Q54968514 | The Influence of Nicotinamide on Health and Disease in the Central Nervous System. |
| Q35763022 | The Molecular Mechanism of Amyloid β42 Peptide Toxicity: The Role of Sphingosine Kinase-1 and Mitochondrial Sirtuins |
| Q39313679 | The emerging field of epigenetics in neurodegeneration and neuroprotection |
| Q38527233 | The epigenetics of aging and neurodegeneration. |
| Q64859138 | The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease |
| Q34159225 | The plasma membrane redox system is impaired by amyloid β-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. |
| Q35055739 | The redox basis of epigenetic modifications: from mechanisms to functional consequences. |
| Q38532744 | The role of mitochondrial disturbances in Alzheimer, Parkinson and Huntington diseases |
| Q42149605 | Transcriptional signatures mediated by acetylation overlap with early-stage Alzheimer's disease |
| Q34137377 | Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases |
| Q91971215 | s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide |
Search more.